EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Digital Transformation in Pharma Manufacturing | David Holt, FactoryTalk | ISPE 2026 | Pharma Focus Asia
Group Executive Director, FactoryTalk
David Holt is the Group Managing Director at Factory Talk with extensive leadership experience across multiple industries He focuses on innovative software solutions that enable the digital transformation of operations within GxP pharmaceutical and medical deviceregulated industries
Articles
Role of Nutraceutical in Various Diseases - A Review
DeFelice introduced the term nutraceutical in combining the words nutrition and pharmacy and originally defined it as a food or part of a food that provides medical or health benefits including the prevention and treatment of disease A nutraceutical may be a nutrientdense food like spirulina garlic or soy or a specific dietary component
Research Insights
Optimizing the Dose of Pre-Pandemic Influenza Vaccines to Reduce the Infection Attack Rate
Steven Riley Joseph T Wu Gabriel M Leung Background The recent spread of avian influenza in wild birds and poultry may be a precursor to the emergence of a like human pandemic Therefore stockpiles of human prepandemic vaccine targeted at avian strains are being consider
Case Studies
Effect Of Process And Formulation Variables On The Preparation Of Parenteral Paclitaxel-loaded Biodegradable Polymeric Nanoparticles: A Co-surfactant Study
Abstract Recent years have seen significant effort devoted to formulate therapeutic agents in biocompatible nanocomposites such as nanoparticles nanocapsules micellar systems and conjugates as drug delivery systems Application of nanotechnology for diagnosis monitoring disease therapy and control of biological systems was referred to as nanomedicin
Techno Trends
Pfizer Launches First-of-its Kind Innovative Technologies for Hemophilia Patients
Pfizer announced the launch of Hemocraft a modification of the popular video game Minecraft and the HemMobile Striiv Wearable a custom wristband It helps people who suffer with hemophilia with better approaches and activity tracking in the US Hemocraft helps younger individuals with hemophilia years of age to learn the importance of integrating treatment into thei...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Industry 4.0 at Bachem
Elodie Decuypere received her Ph.D in Organic Synthesis from the University of Paris-Saclay with specialization in Click Chemistry. After her Ph.D, Elodie specialized in oligonucleotide chemistry with her two postdoc in ETH Zürich and Roche Basel. In 2020, Elodie joined Bachem as a Specialist Marketing and works on the creation of scientific content for marketing materials.
The Role of Artificial Intelligence in Advancing Pharmacovigilance Systems
Rahul Jaiswal is an Assistant Professor at Hygia College of Pharmacy, Lucknow, and a Research Scholar at Integral University, Lucknow. He has been associated with CSIR-CDRI, Lucknow, and has published several articles. His expertise includes molecular techniques, histopathology, and innovative pharmaceutical research, with contributions to national and international conferences.
Transforming Customer Engagement in Life Sciences Adopting Hybrid Commercial Models (HCMs)
is a Practice Director at the Life Sciences IT Services team, leading commercial technology research and client engagements. He has worked with business and IT leaders on strategy, M&A, and market intelligence. Previously a Consultant at EY, Rohit holds an MBA from FMS, Delhi University, and an engineering degree from NIT Jalandhar.
Incipient Biopharmaceutical Claims of Milk Derived Exosomes
Rakesh K. Tekade is a formulation researcher with of teaching and research experience. He has an explicit experience of over 10 years in teaching various modules for Ph.D, Masters & Bachelors students (@ Universities based in USA, UK, Malaysia, & India). He currently serving as Associate Professor at NIPER-Ahmedabad (An Institute of National Importance Government of India). Prior to this, Dr. Tekade was faculty at International Medical University, Kuala Lumpur, Malaysia. He took his postdoctoral trainings from UT Southwestern Medical Centre, Dallas, Texas, USA and University of Hawaii, Hilo, Hawaii, USA. He is a recipient of Commonwealth Fellowship at University of Central Lancashire, Preston, UK. Recently, Dr Tekade has been listed as Top 2% researcher in the field of Pharmacy and Pharmacology, by Stanford University, USA.
Nupur Vasdev is currently pursuing her PhD in the department of pharmaceutics from NIPER-Ahmedabad. She has completed M.S (Pharm.) in pharmaceutics from NIPER-Raebareli. She is currently working on targeted nano particulate drug delivery for obesity and cancer. Her research focus also includes surface modified exosome drug delivery for cancer and obesity.
Manisha Choudhary is currently pursuing her M.S. (Pharm) in Pharmaceutics at NIPER-Ahmedabad, India. She is currently working on aptamer decorated nanomaterials for improving the targeting. Her work majorly focuses on the improvement of the stability, targeting and robustness of aptamer conjugated nanomaterials for cancer treatment. Her work also focusses on the extraction of natural derived exosomes.
Suryanarayana Polaka is currently pursuing his PhD at NIPER-Ahmedabad, India. He is working in targeted drug delivery systems for the treatment of rheumatoid arthritis and wound healing. He also works on exosome mediated drug delivery. He co-authored 10 peer-reviewed publications in international journals, contributed > 7 international reference book chapters.
Professor Kiran Kalia is a currently serving as Director and Professor at NIPER-Ahmedabad. Her work basically focused on the Proteomic markers for diabetic nephropathy, diabetic retinopathy and metal toxicity studies. Recently she started exploring the exosomes mediated drug delivery for delivering the genes for treating various ailments like cancer, wounds and diabetic nephropathy.
Metabolic Stability
Rajesh Sonti is working as an Assistant Professor since Feb 2020 in Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Hyderabad. He completed PhD from IISc, Bangalore and later worked as a post doc in University of Basel and EPFL-Lausanne for 6.5 years.
Venkata Rao Kaki is working as an Assistant Professor in Department of Chemical Sciences (medicinal chemistry/natural products),NIPER-Hyderabad. He completed PhD from Panjab university, Chandigarh. He has 4 years industrial and 8 years of academic experience.
Siva Nageswara Rao Gajulais pursuing PhD in Department of Pharmaceutical Analysis, NIPER-Hyderabad. He is working in the scientific areas:Drug Metabolism and Pharmacokinetics (DMPK), biomarkers and drug-drug interactions. He did M.S. (Pharm.) in department of pharmaceutical Analysisfrom NIPER-Ahmedabad.
Pursued M.S. (Pharm.), National Institute of Pharmaceutical Education and Research (NIPER)
Megha Sajakumar Pillai pursued M.S. (Pharm.) in department of pharmaceutical Analysis, NIPER-Hyderabad. She is currently pursuing PhD in NIPER-Ahmedabad.
press releasesRead more...
Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026
As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders
Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform
Integrated DNA Technologies IDT a Danaher company and a global leader in genomics and Ansa Biotechnologies Inc a trusted partner for DNA synthesis today announced an expansion of their partnership
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience
Biocytogen Pharmaceuticals Beijing Co Ltd Biocytogen SSE HKEX today announced that it has entered into a nonexclusive licensing agreement with Qilu Pharmaceutical Co Ltd
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Heidelberg Pharma AG FSE HPHA a clinicalstage biotech company developing innovative Antibody Drug Conjugates ADCs today announced that its whollyowned subsidiary Heidelberg Pharma Research
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Eisai Co Ltd and Biogen Inc Nasdaq BIIB announced today that the National Medical Products Administration NMPA of China has approved the subcutaneous formulation subcutaneous autoinjector SCAI
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
Roche announced today new twoyear data from the Phase IIIbIV SALWEEN study of Vabysmo faricimab presented at the th AsiaPacific Vitreoretina Society APVRS Congress in Australia
EventsRead more...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026
As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders
HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy
HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPLA an investigational antibodytargeted therapy conjugate ATTC designed to target KRAS and EGFR in solid tumours
Everest Medicines Receives Approval for CARDAMYST to Treat Acute PSVT
Everest Medicines has received approval from Chinas National Medical Products Administration NMPA for CARDAMYST etripamil nasal spray for the conversion of acute symptomatic episodes
HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy
Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine
Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains
Cipla Enters into Agreement with SBP Group for HER2 bispecific ADC TQB2102
Cipla and Sino Biopharmaceutical SBP Group have entered into an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan also known as TQB a HERtargeted bispecific antibodydrug conjugate ADC being developed for the treatment of cancer